Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.
4 reports, 1 independent
Updated Aug 4
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
-
Morgan Stanley
U.S. investment bank
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
- Morgan Stanley and Cantor Fitzgerald raised target prices, while filings detailing stock changes were submitted to the SEC.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald, Morgan Stanley, and Royal Bank of Canada issued price target updates for Elevance Health, Inc. on September 12, 2026.